论文部分内容阅读
目的探讨宫颈癌放化疗期间出现更年期综合征的患者应用莉芙敏治疗的作用及安全性。方法 26例宫颈癌合并更年期综合征患者,放化疗期间予以莉芙敏治疗,选择年龄大小、治疗方法、临床期别、复发部位、身体状况、更年期症状相近、同期治疗的26例宫颈癌患者作为对照组,对比分析两组患者的KMI评分、放化疗不良反应、近期疗效。结果莉芙敏组治疗4周和6周的KMI总分和各单项分均优于对照组。莉芙敏组胃肠道反应低于对照组,差异有统计学意义(P=0.029)。肝功能损伤及骨髓抑制两组无统计学差异。结论莉芙敏治疗宫颈癌患者的更年期症状是安全有效的,同时增强患者对放化疗的耐受性。
Objective To investigate the role and safety of Livmin in the treatment of patients with climacteric syndrome during radiotherapy and chemotherapy of cervical cancer. Methods 26 patients with cervical cancer complicated with climacteric syndrome were treated with Livmin during the radiotherapy and chemotherapy period. 26 patients with cervical cancer treated by the same period of treatment were selected as the age, treatment method, clinical stage, relapse site, physical condition and menopause symptoms. The control group, comparative analysis of two groups of patients KMI score, radiotherapy and chemotherapy side effects, short-term efficacy. Results Livmin group at 4 weeks and 6 weeks KMI score and individual sub-scores were better than the control group. The gastrointestinal reaction in the Livmin group was lower than that in the control group, with a significant difference (P = 0.029). There was no significant difference in liver function and bone marrow suppression between the two groups. Conclusions Livmin is safe and effective in the treatment of menopausal symptoms in cervical cancer patients, and at the same time enhances the patient’s tolerance to radiotherapy and chemotherapy.